bupropion has been researched along with Sex Disorders in 31 studies
Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Bupropion was administered 75 mg twice daily for twelve weeks." | 7.30 | The effects of bupropion on sexual dysfunction in female patients with multiple sclerosis: A double-blind randomized clinical trial. ( Azizi, H; Baghbanian, SM; Bakhshi, A; Ghazaeian, M; Khalili, B, 2023) |
| "Bupropion is an antidepressive medication used for smoking cessation and also has been previously studied for the treatment of sexual dysfunction." | 6.78 | Bupropion for control of hot flashes in breast cancer survivors: a prospective, double-blind, randomized, crossover, pilot phase II trial. ( Del Giglio, A; Fonseca, F; Nuñez, GR; Pinczowski, H; Schindler, F; Tateyama, L; Zanellato, R, 2013) |
| "Bupropion may be an alternative treatment for depression that does not include the sexual side effects associated with most of the prescribed antidepressants available; however, additional research is required." | 6.50 | Bupropion in the depression-related sexual dysfunction: a systematic review. ( Arias-Carrión, O; Machado, S; Nardi, AE; Pereira, VM; Silva, AC, 2014) |
| " This paper reviews the prevalence of sexual dysfunction, weight gain and emotional detachment during SSRI treatment, the profile of bupropion for each of these events and the ability of bupropion to reverse them." | 4.84 | Review: Bupropion and SSRI-induced side effects. ( Demyttenaere, K; Jaspers, L, 2008) |
| "Bupropion was administered 75 mg twice daily for twelve weeks." | 3.30 | The effects of bupropion on sexual dysfunction in female patients with multiple sclerosis: A double-blind randomized clinical trial. ( Azizi, H; Baghbanian, SM; Bakhshi, A; Ghazaeian, M; Khalili, B, 2023) |
| "Bupropion is a dopamine reuptake inhibitor which can potentially improve erectile function among male patients on methadone (MMT)." | 2.87 | Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of Bupropion as Treatment for Methadone-Emergent Sexual Dysfunction in Men. ( Loh, HS; Ng, CG; Ong, TA; Sulaiman, AH; Yee, A, 2018) |
| "Bupropion is an antidepressive medication used for smoking cessation and also has been previously studied for the treatment of sexual dysfunction." | 2.78 | Bupropion for control of hot flashes in breast cancer survivors: a prospective, double-blind, randomized, crossover, pilot phase II trial. ( Del Giglio, A; Fonseca, F; Nuñez, GR; Pinczowski, H; Schindler, F; Tateyama, L; Zanellato, R, 2013) |
| " Bupropion-SR in a daily dosage of 150 mg seemed to be of limited benefit in lifelong DE." | 2.76 | Primary lifelong delayed ejaculation: characteristics and response to bupropion. ( Abdel-Hamid, IA; Saleh, el-S, 2011) |
| "Bupropion is an effective treatment for male SD induced by SSRIs." | 2.75 | The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor: a double-blind placebo-controlled and randomized study. ( Safarinejad, MR, 2010) |
| "Fluoxetine, however, was more frequently associated with sexual dysfunction compared with bupropion SR." | 2.70 | A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine. ( Ascher, J; Batey, S; Bolden-Watson, C; Book, MJ; Coleman, CC; Jamerson, B; King, BR; Metz, A; Richard, N; Segraves, RT, 2001) |
| "Bupropion may be an alternative treatment for depression that does not include the sexual side effects associated with most of the prescribed antidepressants available; however, additional research is required." | 2.50 | Bupropion in the depression-related sexual dysfunction: a systematic review. ( Arias-Carrión, O; Machado, S; Nardi, AE; Pereira, VM; Silva, AC, 2014) |
| "Bupropion has been shown to have a favorable effect on sexual dysfunction." | 2.43 | Effect of bupropion on sexual dysfunction. ( Fader, JS; Ginzburg, R; Wong, Y, 2005) |
| "Anecdotal reports have suggested that the long-term use of selective serotonin reuptake inhibitors (SSRIs) may be associated with significant weight gain, sexual dysfunction, drug interactions, and discontinuation symptoms." | 2.41 | Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine. ( Gupta, S; Masand, PS, 2002) |
| "Despite the superior side effect profile of the newer antidepressants over the tricyclics and monoamine oxidase inhibitors, all newer antidepressants are associated with a wide array of side effects." | 1.31 | The pharmacologic management of SSRI-induced side effects: a survey of psychiatrists. ( Dording, CM; Fava, M; Gordon, J; Kornbluh, R; Mischoulon, D; Nierenberg, AA; Petersen, TJ; Rosenbaum, JE, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.23) | 18.7374 |
| 1990's | 3 (9.68) | 18.2507 |
| 2000's | 12 (38.71) | 29.6817 |
| 2010's | 13 (41.94) | 24.3611 |
| 2020's | 2 (6.45) | 2.80 |
| Authors | Studies |
|---|---|
| Baghbanian, SM | 3 |
| Khalili, B | 3 |
| Bakhshi, A | 3 |
| Azizi, H | 3 |
| Ghazaeian, M | 3 |
| Ramli, FF | 1 |
| Azizi, MH | 1 |
| Syed Hashim, SA | 1 |
| Yee, A | 1 |
| Loh, HS | 1 |
| Ong, TA | 1 |
| Ng, CG | 1 |
| Sulaiman, AH | 1 |
| Hobbs, K | 1 |
| Handler, L | 1 |
| Taylor, MJ | 2 |
| Rudkin, L | 1 |
| Bullemor-Day, P | 1 |
| Lubin, J | 1 |
| Chukwujekwu, C | 1 |
| Hawton, K | 1 |
| Bijlsma, EY | 1 |
| Chan, JS | 1 |
| Olivier, B | 1 |
| Veening, JG | 1 |
| Millan, MJ | 1 |
| Waldinger, MD | 1 |
| Oosting, RS | 1 |
| Graf, H | 1 |
| Walter, M | 2 |
| Metzger, CD | 1 |
| Abler, B | 2 |
| Lai, CH | 1 |
| Pereira, VM | 1 |
| Arias-Carrión, O | 1 |
| Machado, S | 1 |
| Nardi, AE | 1 |
| Silva, AC | 1 |
| Safarinejad, MR | 1 |
| Abdel-Hamid, IA | 1 |
| Saleh, el-S | 1 |
| Seeringer, A | 1 |
| Hartmann, A | 1 |
| Grön, G | 1 |
| Metzger, C | 1 |
| Stingl, J | 1 |
| Clark, SL | 1 |
| Adkins, DE | 1 |
| Aberg, K | 1 |
| Hettema, JM | 1 |
| McClay, JL | 1 |
| Souza, RP | 1 |
| van den Oord, EJ | 1 |
| Nuñez, GR | 1 |
| Pinczowski, H | 1 |
| Zanellato, R | 1 |
| Tateyama, L | 1 |
| Schindler, F | 1 |
| Fonseca, F | 1 |
| Del Giglio, A | 1 |
| Dording, CM | 1 |
| Mischoulon, D | 1 |
| Petersen, TJ | 1 |
| Kornbluh, R | 1 |
| Gordon, J | 1 |
| Nierenberg, AA | 1 |
| Rosenbaum, JE | 1 |
| Fava, M | 1 |
| Masand, PS | 1 |
| Gupta, S | 1 |
| Clayton, AH | 2 |
| Warnock, JK | 1 |
| Kornstein, SG | 1 |
| Pinkerton, R | 1 |
| Sheldon-Keller, A | 1 |
| McGarvey, EL | 1 |
| Martínez-Raga, J | 1 |
| Sabater, A | 1 |
| Cervera, G | 1 |
| Zisook, S | 1 |
| Rush, AJ | 1 |
| Haight, BR | 2 |
| Clines, DC | 1 |
| Rockett, CB | 1 |
| Ginzburg, R | 1 |
| Wong, Y | 1 |
| Fader, JS | 1 |
| Basson, R | 1 |
| Brotto, LA | 1 |
| Laan, E | 1 |
| Redmond, G | 1 |
| Utian, WH | 1 |
| Kennedy, SH | 1 |
| Fulton, KA | 1 |
| Bagby, RM | 1 |
| Greene, AL | 1 |
| Cohen, NL | 1 |
| Rafi-Tari, S | 1 |
| Thase, ME | 1 |
| Thompson, AH | 1 |
| Modell, JG | 1 |
| Johnston, JA | 2 |
| Demyttenaere, K | 1 |
| Jaspers, L | 1 |
| Edens, N | 1 |
| Newton, WP | 1 |
| Croft, H | 1 |
| Settle, E | 1 |
| Houser, T | 1 |
| Batey, SR | 1 |
| Donahue, RM | 1 |
| Ascher, JA | 1 |
| Thompson, TL | 1 |
| Coleman, CC | 1 |
| King, BR | 1 |
| Bolden-Watson, C | 1 |
| Book, MJ | 1 |
| Segraves, RT | 1 |
| Richard, N | 1 |
| Ascher, J | 1 |
| Batey, S | 1 |
| Jamerson, B | 1 |
| Metz, A | 1 |
| Gardner, EA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effects of a High Eicosapentaenoic Acid Multinutrient Supplement on Measures of Stress, Anxiety and Depression in Young Adults: a Randomised, Double-blind, Placebo-controlled Trial.[NCT04844034] | 94 participants (Anticipated) | Interventional | 2022-04-19 | Recruiting | |||
| Effects of a Tissue Selective Estrogen Complex (TESC) on Depression and the Neural Reward System in the Perimenopause[NCT03740009] | Phase 4 | 20 participants (Actual) | Interventional | 2019-01-02 | Completed | ||
| A Twelve-week, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group, Active Controlled, Escalating Dose Study to Compare the Effects on Sexual Functioning of Bupropion Hydrochloride Extended-release (WELLBUTRIN XL, 150-450 mg/Day) and Exte[NCT00316160] | Phase 4 | 347 participants | Interventional | 2004-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The primary outcome measure is functional magnetic resonance imaging (fMRI) data collected during a Monetary Incentive Delay (MID) Task. All participants will complete the fMRI Monetary Incentive Delay (MID) task at baseline and at 3 weeks. During the task, participants need to select the correct response during win and lose conditions by pressing a button on a button box in the MRI. Participant's blood-oxygen-level dependent (BOLD) activation response (A measurement of oxygen level that is released to neurons since areas of the brain that are thought to be more active or involved in certain tasks require more oxygen to perform the tasks.) is measured while they performed the task in MRI scanner." (NCT03740009)
Timeframe: Baseline to 3 weeks
| Intervention | percent signal change (Mean) | |||||
|---|---|---|---|---|---|---|
| Caudate Baseline | Caudate Posttreatment | Nucleus Accumbens Baseline | Nucleus Accumbens Posttreatment | Putamen Baseline | Putamen Posttreatment | |
| Perimenopausal Women, Depressed | .0704 | .0475 | .0623 | .0280 | .0399 | .0408 |
The second primary outcome measure uses the Mood and Anxiety Symptoms Questionnaire - Anhedonic Depression Scale (MASQ-AD) to examine symptom change. All participants will complete the MASQ-AD at each study visit, which measures their current symptoms of depression and anxiety. Scores range from 22 to 110 with lower scores reflecting a better outcome. (NCT03740009)
Timeframe: Baseline, week 2, week 3, week 4 (post treatment)
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline Week 1 | Week 2 | Week 3 | Post Treatment Week 4 | |
| Perimenopausal Women, Depressed | 72.1 | 62.4 | 57.2 | 54.5 |
12 reviews available for bupropion and Sex Disorders
| Article | Year |
|---|---|
Treatments of Sexual Dysfunction in Opioid Substitution Therapy Patients: A Systematic Review and Meta-Analysis.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Humans; Opiate Substitution Treatment; Panax; P | 2021 |
Clinical Inquiry: which treatments help women with reduced libido?
Topics: Administration, Cutaneous; Antidepressive Agents, Second-Generation; Bupropion; Female; Humans; Libi | 2013 |
Strategies for managing sexual dysfunction induced by antidepressant medication.
Topics: Antidepressive Agents; Bupropion; Carbolines; Drug Substitution; Female; Humans; Male; Phosphodieste | 2013 |
Sexual side effects of serotonergic antidepressants: mediated by inhibition of serotonin on central dopamine release?
Topics: Animals; Antidepressive Agents; Aza Compounds; Brain; Bridged Bicyclo Compounds, Heterocyclic; Bupro | 2014 |
Antidepressant-related sexual dysfunction - perspectives from neuroimaging.
Topics: Animals; Antidepressive Agents; Brain; Bupropion; Female; Functional Neuroimaging; Humans; Magnetic | 2014 |
Bupropion in the depression-related sexual dysfunction: a systematic review.
Topics: Bupropion; Databases, Bibliographic; Depression; Female; Humans; Male; Selective Serotonin Reuptake | 2014 |
Drugs for female sexual dysfunction.
Topics: Animals; Bupropion; Contraceptives, Oral; Dyspareunia; Estrogens; Female; Humans; Pharmaceutical Pre | 2010 |
Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Drug Interactions; Humans; Mians | 2002 |
Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Drug Interactions; Humans; Mians | 2002 |
Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Drug Interactions; Humans; Mians | 2002 |
Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Drug Interactions; Humans; Mians | 2002 |
Use of bupropion in combination with serotonin reuptake inhibitors.
Topics: Bupropion; Clinical Trials as Topic; Depressive Disorder, Major; Drug Synergism; Drug Therapy, Combi | 2006 |
Effect of bupropion on sexual dysfunction.
Topics: Animals; Antidepressive Agents, Second-Generation; Bupropion; Clinical Trials as Topic; Humans; Rand | 2005 |
Strategies for managing antidepressant-induced sexual dysfunction: a review.
Topics: Antidepressive Agents; Bupropion; Buspirone; Depressive Disorder; Erectile Dysfunction; Female; Gink | 2006 |
Review: Bupropion and SSRI-induced side effects.
Topics: Affective Symptoms; Bupropion; Depression; Dopamine Uptake Inhibitors; Drug Interactions; Drug Thera | 2008 |
12 trials available for bupropion and Sex Disorders
| Article | Year |
|---|---|
The effects of bupropion on sexual dysfunction in female patients with multiple sclerosis: A double-blind randomized clinical trial.
Topics: Bupropion; Double-Blind Method; Fatigue; Female; Humans; Multiple Sclerosis; Quality of Life; Sexual | 2023 |
The effects of bupropion on sexual dysfunction in female patients with multiple sclerosis: A double-blind randomized clinical trial.
Topics: Bupropion; Double-Blind Method; Fatigue; Female; Humans; Multiple Sclerosis; Quality of Life; Sexual | 2023 |
The effects of bupropion on sexual dysfunction in female patients with multiple sclerosis: A double-blind randomized clinical trial.
Topics: Bupropion; Double-Blind Method; Fatigue; Female; Humans; Multiple Sclerosis; Quality of Life; Sexual | 2023 |
The effects of bupropion on sexual dysfunction in female patients with multiple sclerosis: A double-blind randomized clinical trial.
Topics: Bupropion; Double-Blind Method; Fatigue; Female; Humans; Multiple Sclerosis; Quality of Life; Sexual | 2023 |
The effects of bupropion on sexual dysfunction in female patients with multiple sclerosis: A double-blind randomized clinical trial.
Topics: Bupropion; Double-Blind Method; Fatigue; Female; Humans; Multiple Sclerosis; Quality of Life; Sexual | 2023 |
The effects of bupropion on sexual dysfunction in female patients with multiple sclerosis: A double-blind randomized clinical trial.
Topics: Bupropion; Double-Blind Method; Fatigue; Female; Humans; Multiple Sclerosis; Quality of Life; Sexual | 2023 |
The effects of bupropion on sexual dysfunction in female patients with multiple sclerosis: A double-blind randomized clinical trial.
Topics: Bupropion; Double-Blind Method; Fatigue; Female; Humans; Multiple Sclerosis; Quality of Life; Sexual | 2023 |
The effects of bupropion on sexual dysfunction in female patients with multiple sclerosis: A double-blind randomized clinical trial.
Topics: Bupropion; Double-Blind Method; Fatigue; Female; Humans; Multiple Sclerosis; Quality of Life; Sexual | 2023 |
The effects of bupropion on sexual dysfunction in female patients with multiple sclerosis: A double-blind randomized clinical trial.
Topics: Bupropion; Double-Blind Method; Fatigue; Female; Humans; Multiple Sclerosis; Quality of Life; Sexual | 2023 |
Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of Bupropion as Treatment for Methadone-Emergent Sexual Dysfunction in Men.
Topics: Adult; Bupropion; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedul | 2018 |
The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor: a double-blind placebo-controlled and randomized study.
Topics: Adult; Bupropion; Depressive Disorder, Major; Dopamine Uptake Inhibitors; Epidemiologic Methods; Hum | 2010 |
Primary lifelong delayed ejaculation: characteristics and response to bupropion.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Ejaculation; Humans; Male; Orgasm; Prola | 2011 |
Neural correlates of antidepressant-related sexual dysfunction: a placebo-controlled fMRI study on healthy males under subchronic paroxetine and bupropion.
Topics: Adult; Antidepressive Agents; Bupropion; Dopamine Uptake Inhibitors; Double-Blind Method; Humans; Li | 2011 |
Pharmacogenomic study of side-effects for antidepressant treatment options in STAR*D.
Topics: Antidepressive Agents; Bupropion; Citalopram; Depressive Disorder, Major; Drug-Related Side Effects | 2012 |
Bupropion for control of hot flashes in breast cancer survivors: a prospective, double-blind, randomized, crossover, pilot phase II trial.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Breast Neoplasms; Bupropion; Cross-Over Studi | 2013 |
A placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor-induced sexual dysfunction.
Topics: Administration, Oral; Adult; Antidepressive Agents, Second-Generation; Arousal; Bupropion; Delayed-A | 2004 |
Sexual function during bupropion or paroxetine treatment of major depressive disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Bupropion; Depressive Disorder, M | 2006 |
A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Depressive Disorder, Majo | 2006 |
A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline.
Topics: Adult; Aged; Bupropion; Delayed-Action Preparations; Depressive Disorder, Major; Dopamine Uptake Inh | 1999 |
A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action Preparations; Depressive | 2001 |
7 other studies available for bupropion and Sex Disorders
| Article | Year |
|---|---|
Bupropion-related sexual dysfunction and possible management in a fresh patient with major depressive disorder.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Depressive Disorder, Major; Humans; Male; Phosp | 2014 |
The pharmacologic management of SSRI-induced side effects: a survey of psychiatrists.
Topics: Akathisia, Drug-Induced; Antidepressive Agents, Second-Generation; Bupropion; Critical Pathways; Dat | 2002 |
Anorgasmia in a patient treated with bupropion SR for smoking cessation.
Topics: Adult; Bupropion; Humans; Male; Sexual Dysfunction, Physiological; Smoking; Smoking Cessation | 2004 |
Assessment and management of women's sexual dysfunctions: problematic desire and arousal.
Topics: Adult; Androgens; Bupropion; Depression; Diagnostic and Statistical Manual of Mental Disorders; Dopa | 2005 |
SSRIs, bupropion, and sexual function.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Coitus; Depressive Disorder; Humans; Rep | 1997 |
Forum: what are the best ways to treat sexual problems caused by SSRIs?
Topics: Antidepressive Agents, Second-Generation; Bupropion; Female; Humans; Male; Phosphodiesterase Inhibit | 1999 |
Bupropion--an antidepressant without sexual pathophysiological action.
Topics: Adult; Antidepressive Agents; Bupropion; Female; Humans; Male; Middle Aged; Propiophenones; Sexual D | 1985 |